CPC 405
Latest Information Update: 17 Apr 2001
Price :
$50 *
At a glance
- Originator Questcor Pharmaceuticals
- Class Anti-ischaemics; Cytoprotectives; Small molecules
- Mechanism of Action Adenosine deaminase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cerebral ischaemia; Ischaemic heart disorders
Most Recent Events
- 17 Apr 2001 Discontinued-Preclinical for Cerebral ischaemia in USA (Unknown route)
- 17 Apr 2001 Discontinued-Preclinical for Ischaemic heart disorders in USA (Unknown route)
- 20 Dec 1999 Cypros Pharmaceutical has merged with RiboGene to form Questcor Pharmaceuticals